ArticleActa biochimica et biophysica Sinica2024
Gallic acid attenuates LPS-induced inflammation in Caco-2 cells by suppressing the activation of the NF-κB/MAPK signaling pathway.
Article in Acta biochimica et biophysica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 21 citations in OpenAlex.
- Tafolecimab mitigates ox-LDL-induced macrophage foam cell formation and inflammation by modulating SR-A/ABCG1 expression and inhibiting the NF-κB/MAPK pathways.Biomedical reports · 2026Article
- Intestinal Epithelial-Protective Effects ofJournal of microbiology and biotechnology · 2026Article
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- A Novel Approach for Reducing Enteropathogens Using LAB-Fermented Whey Solution and UV-C Light-Activated Gallic Acid.Foods (Basel, Switzerland) · 2026Article
- Anti-Complement, Anti-Oxidative, and Anti-Inflammatory Activities of the Ethanol Extract ofPlants (Basel, Switzerland) · 2026Article
- Extremophyte-derived exosome-like nanovesicles remodel intestinal barrier dysfunction by multi-dimensional intervention: physical barrier repair with immune homeostasis and microbiome regulation.Journal of nanobiotechnology · 2026Article
- Neuroprotective effects of gallic acid in an MPP⁺-induced SH-sy5y cell model of parkinson's disease.Molecular biology reports · 2026Article
- Gallic acid attenuates LPS-induced acute kidney injury with accompanying changes in inflammatory and redox-related signaling pathways.Molecular biology reports · 2026Article
- A ROS-responsive nanozyme delivering gallic acid synergistically ameliorates chronic rhinosinusitis via epithelial barrier restoration and Syk/NF-κB inhibition.International journal of pharmaceutics: X · 2026Article
- Recent Advances in Natural Products for Colitis: Mechanisms and Translational Perspectives.Veterinary sciences · 2026Review
- Investigating the protective effect of zinc oxide-gallic acid nanoparticles against depression like behavior and memory impairment in animals treated with D-galactose.Scientific reports · 2026Article
- Elucidating Trigonelline's Therapeutic Mechanisms for Traumatic Brain Injury Through Integrated Network Pharmacology and In Vivo Validation.CNS neuroscience & therapeutics · 2026Article
- Synergistic anti-inflammatory effects of the aqueous extract from Desmodium heterophyllum and photobiomodulation in a carrageenan-induced paw edema model.Lasers in medical science · 2026Article
- Article
- Cardioprotective effects of gallic acid in a rat ischemia-reperfusion model: role of apoptosis, inflammation, and antioxidant defense.Research in pharmaceutical sciences · 2026Article
- New Insights into Cranberry Bioactivity: Polyphenol Composition, Adhesive Effects Against Food Spoilage Yeasts, and Influence on Intestinal Cells.Molecules (Basel, Switzerland) · 2026Article
- Integrative network pharmacology and experimental validation of rubus ulmifolius leaf extract in a rat model of MRSA-infected wounds.Inflammopharmacology · 2026Article
- Targeting mitochondrial metabolism to overcome hormone resistance in breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Targeting mitochondrial dysfunction with traditional Chinese medicine for inflammatory bowel disease: a comprehensive review.Frontiers in pharmacology · 2026Review
- Orally administered gallic acid nanoparticles adhere to intestine via in-situ gelation for enhanced UC treatment.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disease characterized by intestinal barrier dysfunction, inflammatory synergistic effects and excessive tissue injury. Gallic acid (GA) is renowned for its remarkable biological activity, encompassing anti-inflammatory and antioxidant properties. However, the underlying mechanisms by which GA protects against intestinal inflammation have not been fully elucidated. The aim of this study is to investigate the effect of GA on the inflammation of a lipopolysaccharide (LPS)-stimulated human colon carcinoma cell line (Caco-2) and on the intestinal barrier dysfunction, and explore the underlying molecular mechanism involved. Our findings demonstrate that 5 μg/mL GA restores the downregulation of the mRNA and protein levels of Claudin-1, Occludin, and ZO-1 and decreases the expressions of inflammatory factors such as IL-6, IL-1β and TNF-α induced by LPS. In addition, GA exhibits a protective effect by reducing the LPS-enhanced early and late apoptotic ratios, downregulating the mRNA levels of pro-apoptotic factors (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.